Tag: First-line bladder cancer breakthrough

Home / First-line bladder cancer breakthrough

Categories

Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial cancer

As of December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) along with pembrolizumab (Keytruda, Merck) for people who have locally advan...
first-line-bladder-cancer-breakthrough

Scan the code